Drug Profile
ZM 230487
Alternative Names: ICI 230487Latest Information Update: 08 Feb 2008
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Osteoporosis therapies
- Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for Postmenopausal osteoporosis in United Kingdom (unspecified route)
- 08 Feb 2008 Discontinued - Preclinical for Postmenopausal osteoporosis in USA (unspecified route)
- 07 Apr 1999 Merger of Zeneca and Astra to form AstraZeneca completed